Severe transplant‐associated thrombotic microangiopathy in patients with hemoglobinopathies

Citations Over TimeTop 19% of 2017 papers

Abstract

Incidence and severity of transplant-associated thrombotic microangiopathy (TA-TMA) in patients with hemoglobinopathies receiving hematopoietic cell transplant is unknown. We report the outcomes for two patients with TA-TMA who received eculizumab. A 2.5-year-old male with sickle cell disease developed TA-TMA-associated pericardial tamponade, severe hypertension, and acute kidney injury 2 months after transplant. A 7-year-old female with β-thalassemia major developed TA-TMA-related acute kidney injury, severe hypertension, and seizures at 6 months after transplant. Both patients progressed to chronic kidney disease (CKD). In patients with hemoglobinopathies, preexisting endothelial dysfunction may place them at a greater risk for TA-TMA and subsequent CKD.

Related Papers

• → Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy(2015)132 cited
• → Two cases of kidney transplantation‐associated thrombotic microangiopathy successfully treated with eculizumab(2016)27 cited
• → The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome(2020)18 cited
• → 231 Acute Kidney Injury due to Thrombotic Microangiopathy From Catastrophic Antiphospholipid Syndrome Treated With Eculizumab(2022)2 cited
• → An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report(2015)8 cited